The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.

The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

PanEcho isn’t yet ready to be a standalone tool, researchers say, but shows promise at improving workflows and patient care.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.